Related Experiment Video
Updated: Jul 16, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
[Treatment of hyperphosphatemia in hemodialysis patients]
1Service de néphrologie, hôpital Maison-Blanche, 45, rue Cognacq-Jay, 51092 Reims, France. prieu@chu-reims.fr
Insights
Managing hyperphosphatemia is crucial for hemodialysis patients to prevent complications like hyperparathyroidism and reduce mortality. This review covers dietary, dialytic, and pharmacologic strategies, including phosphate binders and nicotinamide.
Area of Science:
- Nephrology
- Endocrinology
- Internal Medicine
Context:
- Hyperphosphatemia is a significant complication in hemodialysis patients, linked to secondary hyperparathyroidism, extraosseous calcification, and increased mortality.
- Current guidelines, such as NFK-KDOQI 2003, advocate for strict serum phosphorus control within the range of 1.13–1.78 mmol/l.
Purpose:
- This review critically examines multifaceted strategies for managing hyperphosphatemia in patients undergoing dialysis.
- It aims to provide an updated overview of therapeutic approaches, including dietary modifications, enhanced dialysis, phosphate binders, nicotinamide, and parathyroid hormone level management.
Summary:
- Effective hyperphosphatemia management involves a comprehensive approach: reducing dietary phosphorus, optimizing phosphate removal during dialysis, utilizing phosphate binders (both traditional and novel calcium-free options), considering nicotinamide therapy, and controlling parathyroid hormone levels.
- The review also re-evaluates recent recommendations regarding the restriction of supplemental elemental calcium intake to 1.5 g daily.
Impact:
- Optimizing hyperphosphatemia treatment can significantly improve patient outcomes by mitigating secondary hyperparathyroidism and reducing calcification risks.
- This review supports clinicians in refining patient management strategies, potentially leading to decreased mortality rates in the hemodialysis population.
Abstract:
Hyperphosphatemia plays a key role in the development of hyperparathyroidism and extraosseous calcification and is associated with increased mortality in hemodialysis patients. The treatment of hyperphosphatemia therefore represents a cornerstone in the management of dialyzed patients. NFK-KDOQI 2003 has recommended rigorous control of serum phosphorus to between 1.13-1.78 mmol/l. A multiple-factor approach can be used to reduce serum phosphate: 1) reduce phosphorous intake in the diet; 2) increase phosphate removal by dialytic treatment; 3) use old and new phosphate binders; 4) treat with nicotinamide; and 5) control serum parathyroid hormone levels. All these points are discussed in this review. Recent recommendations for supplemental elemental calcium restriction to 1.5 g per day are reconsidered and indications of new calcium-free phosphate binders are examined.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Hemodialysis III: Nursing Management
Peritoneal Dialysis III: Nursing Management
Acute Kidney Injury V: Interprofessional Care
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction